Japanese drug major Otsuka Pharmaceutical (TYO: 4578) has entered into an exclusive license agreement for the joint development and commercialization in Japan of the investigational oncolytic virus HF10 therapy (HF10) for the treatment of pancreatic cancer, melanoma and other tumors developed by Takara Bio (TYO: 4974).
HF10 is an attenuated strain of Herpes simplex virus type 1 (HSV-1), an oncolytic virus which in clinical trials to date has demonstrated antitumor activity when injected into cancerous areas. Oncolytic viruses, which rarely proliferate in normal cells, destroy cancer cells directly by proliferating inside them.
Deal worth up to 3 billion yen
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze